D. MacLean

发表

Double‐blind, randomized, placebo‐controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK‐683, an investigational metastin analogue in healthy men

C. Oliva, G. Scott, S. Warrington, 2013, British journal of clinical pharmacology.

Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer

M. Gross, J. Hainsworth, L. Hart, 2014, Clinical Cancer Research.

The effects of radiation therapy on the macrophage response in cancer

J. N. Arnold, M. Olcina, D. MacLean, 2022, Frontiers in Oncology.

Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.

F. Saad, H. Faessel, H. Shi, 2015, The Journal of clinical endocrinology and metabolism.

Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.

R. Neuwirth, M. Colombel, H. Matsui, 2014, The Journal of clinical endocrinology and metabolism.

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

J. Sylvester, F. Saad, D. Dearnaley, 2020, European urology.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.

2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts)

F. Saad, N. Shore, C. Pieczonka, 2015 .

Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study.

D. Agus, W. Stadler, R. Dreicer, 2010 .

Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).

F. Saad, N. Shore, C. Pieczonka, 2016 .

A Phase 1, Randomized, Single‐Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK‐700) in Healthy Male Subjects

D. MacLean, Theresa T. Pham, A. Suri, 2016, Clinical pharmacology in drug development.

Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC)

J. Sylvester, D. Dearnaley, N. Shore, 2016 .

PD28-01 TESTOSTERONE LOWERING, PSA RESPONSE AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED HORMONE SENSITIVE PROSTATE CANCER RECEIVING TAK-385, AN ORAL GNRH ANTAGONIST: PHASE 2 INTERIM ANALYSIS

F. Saad, N. Shore, C. Pieczonka, 2016 .

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

F. Saad, H. Scher, G. Heller, 2016, Clinical Cancer Research.

Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations.

O. Sartor, K. Beusterien, E. Flood, 2015, Clinical genitourinary cancer.

7014 POSTER DISCUSSION Evaluation of Circulating Tumour Cells (CTCs) in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Receiving TAK-700, an Investigational 17,20-lyase Inhibitor

M. Gross, D. Agus, R. Dreicer, 2011 .

A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, H. Akaza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.

M. Gross, J. Hainsworth, L. Hart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

F. Saad, J. Nelson, H. Scher, 2015, The Lancet. Oncology.